PHASE-II STUDY OF 13-CIS-RETINOIC ACID PLUS INTERFERON-ALPHA(2A) IN HEAVILY PRETREATED SQUAMOUS CARCINOMA OF THE CERVIX

被引：23

作者：

HALLUM, AV

ALBERTS, DS

LIPPMAN, SM

INCLAN, L

SHAMDAS, GJ

CHILDERS, JM

SURWIT, EA

MODIANO, M

HATCH, KD

机构：

[1] UNIV ARIZONA,COLL MED,ARIZONA CANC CTR,TUCSON,AZ 85724

[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORSAC HEAD & NECK MED ONCOL,HOUSTON,TX 77030

[3] TUCSON MED CTR,CANC CARECTR SO ARIZONA,TUCSON,AZ 85724

[4] VET ADM MED CTR,DEPT MED,HEMATOL & ONCOL SECT,FARGO,ND 58102

[5] UNIV ARIZONA,COLL MED,DEPT MED,HEMATOL ONCOL SECT,TUCSON,AZ 85724

来源：

GYNECOLOGIC ONCOLOGY | 1995年 / 56卷 / 03期

关键词：

D O I：

10.1006/gyno.1995.1067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha(2a) has been reported to be highly active in previously untreated squamous carcinoma of the cervix. In this phase II study, 13-cRA was given at a dose of 1 mg/kg/day and IFN-alpha(2a) was given subcutaneously at a dose of 3 million units/m2/day. Thirteen of 14 patients enrolled in this study are evaluable for response and toxicity. There were no complete or partial responses. Ten patients had progressive disease and the remaining three had stable disease. Principle toxicities were fatigue, nausea, and vomiting. This regimen appears cross-resistant with radiotherapy and/or platinum-based cytotoxic therapy in heavily pretreated patients with squamous carcinoma of the cervix. (C) 1995 Academic Press, Inc.

引用

页码：382 / 386

页数：5

共 33 条

[1]

AGARWAL C, 1994, CANCER RES, V54, P2108

[2]

AGARWAL C, 1991, CANCER RES, V51, P3982

[3]

RETINOIDS IN CANCER PREVENTION AND THERAPY [J].